menu
Showcases Stock ranks

Boston Scientific Corporation (BSX) (BSX)
30.61 -0.81 (-2.58%) 03-27 16:02
Open: 30.32 Pre. Close: 31.42
High: 31.39 Low: 29.47
Volume: 11,232,797 Market Cap: 42830M
Boston Scientific Corp is a developer, manufacturer, and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Share on Facebook   Tweet this page
Price Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 31.408 - 31.568 31.568 - 31.691
Low: 29.111 - 29.273 29.273 - 29.397
Close: 30.367 - 30.646 30.646 - 30.86
Stock Technical Analysis
Overall:     
Target: Six months: 41.00
One year: 48.94
Support: Support1: 24.10
Support2: 20.05
Resistance: Resistance1: 35.10
Resistance2: 41.90
Pivot: 30.10
Moving Averages: MA(5): 29.20
MA(20): 32.04
MA(100): 40.85
MA(250): 40.53
MACD: MACD(12,26): -2.81
Signal(12,26,9): -3.14
%K %D: %K(14,3): 50.32
%D(3): 39.56
RSI: RSI(14): 42.67
52-Week: High: 46.62
Low: 24.1
Change(%): -20.8
Average Vol(K): 3-Month: 1109253
10-Days: 1523175
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

BSX has closed below upper band by 45.2%. Bollinger Bands are 126.2% wider than normal. The large width of the bands suggest high volatility as compared to BSX's normal range. The bands have been in this wide range for 21 bars. This is a sign that the current trend might continue.
Stock chart
Stock News
2020-03-28
Proposed Settlement of Canadian BSC Transvaginal Mesh Litigation
TORONTO , March 28, 2020 /CNW/ - Siskinds LLP and Siskinds, Desmeules s.e.n.c.r.l. announced today that a Canada -wide settlement has been reached in a class action related to certain transvaginal mesh devices for treatment of Pelvic Organ Prolapse ("POP") and Stress Urinary Incontinence ("SUI") manufactured and distributed in Canada by Boston Scientific Ltd. and Boston Scientific Corporation ("BSC"). The class action, which was commenced in 2012, alleges various injuries associated with BSC Transvaginal Mesh Devices. The proposed settlement applies to all women resident in Canada who were implanted with one or more of these devices on or before February 28, 2020 and provides for the payment by the Defendants of Full story available on Benzinga.com

2020-03-27
Insights into the U.S. Neurological Devices Market to 2025 - Featuring Axonics, Boston Scientific & Cerenovus Among Others - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Neurological Devices Market Analysis, Size, Trends | US | 2019-2025" report has been added to ResearchAndMarkets.com's offering. This report discusses the medical devices, capital equipment and device accessories used by neurosurgeons. The various segments of the neurological devices market, as well as the conditions they treat, are introduced below. The U.S. market for neuromodulation, neurovascular and neurosurgical devices is collectively referred to as the U.S.

Financial Analysis
Growth NA
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability NA
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency NA
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency NA
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. (M) 1390.00
Shares Float (M) 1390.00
% Held by Insiders 0.25
% Held by Institutions 95.05
Shares Short (K) 11430
Shares Short Prior Month (K) 12960
Stock Financials
EPS 3.330
Book Value (p.s.) 9.950
PEG Ratio 2.08
Profit Margin 43.78
Operating Margin 16.82
Return on Assets (ttm) 4.4
Return on Equity (ttm) 41.6
Qtrly Rev. Growth 13.4
Gross Profit (p.s.) 5.489
Sales Per Share 7.719
EBITDA (p.s.) 2.029
Qtrly Earnings Growth 935.20
Operating Cash Flow (M) 1840.00
Levered Free Cash Flow (M) 1390.00
Stock Valuation
P/E 9.20
P/E Growth Ratio -0.03
P/BV 3.08
P/S
P/CF 23.14
Dividend Yield
Dividends & Splits
Dividend
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio 2

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator